Skip to main content
KBS_Icon_questionmark link-ico
alcohol-bottles ;

NIHR Evidence Highlights ADAM Trial: A Breakthrough in Alcohol Dependence Treatment

NIHR Evidence has chosen to spotlight a recent paper stemming from the ADAM trial, a large multi-centre study led by Professor Colin Drummond (KCL Professor of Addiction Psychiatry) with adherence expertise provided by CARE Director Professor John Weinman. This significant research sheds light on innovative approaches to enhance adherence to acamprosate, a medication for combating alcohol dependence and preventing relapse.

The ADAM trial is a groundbreaking effort in understanding how to best support individuals grappling with alcohol dependence. The study, which included 739 participants, compared strategies aimed at ensuring patients adhere to acamprosate as prescribed, thereby mitigating the risk of relapse.

This exciting research not only offers a potential solution to the pressing issue of medication adherence but also underscores the importance of integrating novel approaches into addiction treatment. The incorporation of telephone support, particularly when administered by pharmacists, demonstrates promise in enhancing patient outcomes while maintaining cost-effectiveness.

The findings of the ADAM trial have already influenced the development of new UK guidelines for alcohol treatment, slated for publication later this year. This underscores the immediate impact of the research in informing clinical practice and policy decisions.

The ADAM trial sets the stage for further exploration into the role of pharmacists in providing adherence support for addiction treatment, and calls for greater awareness among clinicians regarding the value of medications like acamprosate. Moreover, it underscores the imperative for healthcare systems to ensure the availability of and adherence to essential treatments for individuals battling alcohol dependence.

Latest news